Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-[18F]FBFP
- Development stage
- Phase 1
- Lead developer
- Washington University in St. Louis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
(S)-[18F]FBFP is a fluorine-18 labeled radiopharmaceutical that serves as a positron emission tomography (PET) tracer for the sigma-1 receptor (σ1R). The sigma-1 receptor is a molecular chaperone located in the endoplasmic reticulum that modulates various cellular processes, including calcium signaling and protein folding. It is highly expressed in the central nervous system and is implicated in the pathophysiology of neurodegenerative diseases, such as Alzheimer's and Parkinson's, as well as psychiatric disorders like major depression. (S)-[18F]FBFP is the S-enantiomer of a piperazine derivative, chosen for its high affinity and selectivity for σ1R over the sigma-2 receptor. In clinical research, it is used to non-invasively map and quantify σ1R density in the human brain, providing insights into disease mechanisms and facilitating the development of σ1R-targeted therapies by measuring receptor occupancy.
- Other names
- (S)-1-(3-bromo-4-[18F]fluorobenzyl)-4-[(2-fluorophenyl)methyl]piperazine[18F]FBFP
02
Targets
SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on (S)-[18F]FBFP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (S)-[18F]FBFP.